Free tool
FAERS Monitor: Novolin N
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 019959 or its brand name (Novolin N, Insulin Susp Isophane Recombinant Human). Reports on generic versions are filed under their own applications.
Reports
6,504
Serious
4,443
68% of reports
Hospitalization
2,320
Death reported
593
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,003
- blood glucose decreased365
- drug ineffective362
- nausea332
- dyspnoea281
- diarrhoea274
- dizziness234
- fatigue231
- death227
- hypoglycaemia225
- fall213
- malaise208
- headache207
- renal failure206
- weight decreased195
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 150 |
| 2006 | 232 |
| 2007 | 144 |
| 2008 | 191 |
| 2009 | 246 |
| 2010 | 181 |
| 2011 | 144 |
| 2012 | 207 |
| 2013 | 242 |
| 2014 | 330 |
| 2015 | 769 |
| 2016 | 537 |
| 2017 | 568 |
| 2018 | 609 |
| 2019 | 569 |
| 2020 | 286 |
| 2021 | 246 |
| 2022 | 179 |
| 2023 | 138 |
| 2024 | 166 |
| 2025 | 193 |
| 2026 | 86 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,655 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose decreasedSignal | 365 | 24.8 | 22.4 | 8,254 |
| blood glucose increasedSignal | 1,003 | 17.3 | 16.3 | 15,446 |
| hypoglycaemiaSignal | 225 | 15.1 | 13.2 | 2,934 |
| renal failureSignal | 206 | 5.0 | 4.4 | 663 |
| weight decreasedSignal | 195 | 2.3 | 2.0 | 137 |
| fallSignal | 213 | 2.1 | 1.8 | 119 |
| dyspnoea | 281 | 1.6 | 1.4 | 65 |
| malaise | 208 | 1.5 | 1.3 | 39 |
| dizziness | 234 | 1.5 | 1.3 | 42 |
| diarrhoea | 274 | 1.4 | 1.2 | 28 |
| nausea | 332 | 1.4 | 1.2 | 32 |
| headache | 207 | 1.1 | 0.9 | 1 |
| fatigue | 231 | 1.0 | 0.8 | 0 |
| drug ineffective | 362 | 0.9 | 0.8 | 5 |
| death | 227 | 0.9 | 0.7 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.